NSE: ORCHPHARMA · BSE: 524372 · ISIN INE191A01027
Orchid Pharma Limited stock analysis
Orchid Pharma Limited ranks #1661 in the TickerSutra evidence-ranked universe with a score of 51/100 and 95% data confidence. The latest captured fundamentals show ROCE of 1.7%, quarterly sales growth of 15.6% and quarterly profit growth of 156.6%.Monitor only
INVESTMENT EVIDENCE
What supports—and challenges—the thesis
Evidence in favour
- Low debt/equity of 0.28×
- Strong CFO/EBITDA of 2.97×
- 22.8% three-year sales CAGR
- Institutional ownership is rising
- CWIP indicates an active capacity pipeline
- No promoter shares are reported as pledged
Risks and constraints
- Operating margin has compressed materially
- Valuation is above 40× earnings
Still unresolved: Related-party exposure · Broad media sentiment
FINANCIAL TRAJECTORY
Recent operating history
| Period | Revenue | Operating profit | Net profit | Operating margin |
|---|---|---|---|---|
| 2022 | ₹560cr | ₹55cr | ₹-2cr | 10.0% |
| 2023 | ₹666cr | ₹84cr | ₹46cr | 13.0% |
| 2024 | ₹819cr | ₹111cr | ₹92cr | 14.0% |
| 2025 | ₹922cr | ₹118cr | ₹100cr | 13.0% |
| 2026 | ₹1,233cr | ₹34cr | ₹10cr | 2.7% |
| TTM | ₹1,073cr | ₹44cr | ₹11cr | 4.1% |
EXCHANGE EVENT TRIGGERS
Latest corporate disclosures
Orchid Pharma Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
RoutineUpdatesNSE · 23 Sept 2026Orchid Pharma Limited has informed the Exchange regarding 'Intimation under Regulation 30 of SEBI ( Listing obligation and Disclosure Requirement) Regulations, 2015'.
RoutineOrchid Pharma Ltd - 524372 - Intimation Under Regulation 30 Of SEBI (Listing Obligation And Disclosure Requirement Regulations), 2015BSE · 23 Sept 2026Intimation under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015
RoutineUpdatesNSE · 21 Sept 2026Orchid Pharma Limited has informed the Exchange regarding 'Investor Roadshow Scheduled to be held in Mumbai'.
RoutineOrchid Pharma Ltd - 524372 - Investor Roadshow Scheduled To Be Held In MumbaiBSE · 21 Sept 2026Investor roadshow scheduled to be held in Mumbai
MANAGEMENT COMMENTARY
Signals from filed documents
This is among the largest and most complex fermentation projects being executed in the country. It's a critical backward integration project which can provide the advantage of scale to Orchid, and we are putting our best efforts to execute the project successfully. More broadly, while the first quarter has shown improvement, it would be premature to assume a straight-line recovery.
However, these oppor tunities will create value only through consistent execution. We will, therefore, remain focused on operational discipline, prudent capital allocation, regulatory compliance, timely project delivery, and transparent communication with all the stakeholders. Thank you for your continued trust and support in Orchid Pharma.
So, we ourselves have got this waiver, that's why we are more hopeful, actually. And this GARDP RFQ, do you see any registration or regulatory approvals? How does that work because for 125 countries or just WHO enables you to supply to 125 countries , WHO certification?
I just wanted -- I just have two questions. Firstly, it was that as you said that the industry pricing pressure cycle is still on. I wanted to understand what is the Orchid Pharma Limited August 21, 2026 Page 5 of 17 management thinking?
So, my first question is on the 7-ACA project, and I think in line with one of the earlier participants. So, what happened in Pen G with Aurobindo, you know, the way China dumped and the reduced prices, and we have seen that across many APIs where you start new capacity and try to take market share, China is just doing irrational pricing. So, do we have a plan B on that just in case if they decide to dump at a price
I missed it, if you could just repeat that. Mridul Dhanuka: 7-ACA is March 2027, and Cefiderocol, facility would be ready by December, and first product approval will take 6 to 9 months from there for Cefiderocol approval in India depending on DCGI granting the clinical trial waiver. So, that would be Q3 of next financial year.
HOW TO READ THIS PAGE
Evidence, freshness and limitations
What does the TickerSutra score mean?
The score ranks captured evidence across financial quality, growth, moat and margins, regulatory catalysts, governance, institutional trend and valuation comfort. It is a research-prioritization tool—not a buy recommendation or price target.
Which sources support this page?
Financial history, ownership and pledge data, NSE and BSE filings, annual reports and available earnings-call transcripts are combined here. Use the source trail and original exchange document before relying on a decision-critical fact.
Why can an item be unresolved?
Unresolved means the current captured source window did not provide enough evidence for that check. It does not establish that a risk or relationship is absent.
Maintained by TickerSutra Research · Snapshot updated 29 Sept 2026 · Read the methodology · Read the disclaimer
DIRECTOR & BUSINESS NETWORK
Loading corporate intelligence
Loading universe coverage and exchange-backed evidence…